Immunome (IMNM) news
Recent news
Immunome - Has no further payment obligations to BMS under license agreement - SEC filing
AInvest Wire · Oct 5, 2026Immunome - Amendment removes co's milestone & royalty payment obligations and assigns patent rights related to Varegacestat, AL101 - SEC filing
Immunome, Inc. (Nasdaq: IMNM) has executed an amendment to its licensing agreement that removes the company’s obligations related to milestone and royalty payments, while also assigning patent rights for Varegacestat and AL101. The amendment is detailed in a recent SEC filing, reflecting a…
AInvest Wire · Oct 5, 2026Immunome - Enters amendment no. 4 to license agreement with Bristol-Myers Squibb Company on Oct 2, 2026 - SEC filing
On October 2, 2026, Immunome Inc. announced the execution of Amendment No. 4 to its license agreement with Bristol-Myers Squibb Company, as disclosed in a recent SEC filing . The amendment updates the terms of the original agreement, which pertains to the development and commercialization of…
AInvest Wire · Oct 5, 2026Immunome, Inc.: Stifel initiates coverage with hold rating; price target $24
AInvest Wire · Oct 1, 2026Immunome, - To initiate phase 1 study of IM-1340 in Q4 2026
AInvest Wire · Sep 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.